Unmet Needs in Multiple Myeloma Ahead of ASCO 2024

Now Viewing

EP: 1.Unmet Needs in Multiple Myeloma Ahead of ASCO 2024

Video content above is prompted by the following:

• Coming into ASCO 2024, what did you consider to be the largest unmet needs in the treatment and management of multiple myeloma (MM)?
• What are the latest trends and innovations you have observed in the treatment and management of MM leading up to and coming out of ASCO 2024?
• How does relapsed/refractory MM (RRMM), particularly after multiple lines of therapy, affect the quality of life of patients and their families?